RxDoctor Payments Data

John Deberry, MD

Urology · Buffalo, NYNPI 1457314197

Payments from drug & device makers

$3,850in general payments, 2019–2025

Across 162 payments — averaging $23.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Pfizer$596
  • Astellas Pharma US Inc$538
  • Sumitomo Pharma America, Inc.$220
  • Teleflex LLC$109
  • Coloplast$80
  • plus $712 from 17 others

What the payments were for

  • Food & beverage$3,44289%
  • Education$40811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,850 in reported general payments places this provider in the 55th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$61,427
Medicare patients
127
Services billed
1,443

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide13$159,736
MyrbetriqMirabegron246$149,575
GemtesaVibegron119$78,517
OrgovyxRelugolix19$49,090
Mirabegron ErMirabegron42$28,805
ElmironPentosan Polysulfate Sodium21$21,482
Tamsulosin Hcl569$7,367
Trospium Chloride ErTrospium Chloride28$6,608
Cefpodoxime Proxetil69$4,602
Alfuzosin Hcl ErAlfuzosin Hcl121$3,559
Trospium Chloride53$3,494
Tolterodine Tartrate ErTolterodine Tartrate42$3,278
Silodosin42$2,946
Solifenacin Succinate52$2,548
Fesoterodine Fumarate ErFesoterodine Fumarate14$2,453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$1,595$159,73613 claims
Astellas Pharma US IncMyrbetriq$538$149,575246 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$220$127,607138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 952 urology providers in New York.

Other urology in Buffalo

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →